Keywords: رانیبیزوماب; Diabetic macular edema; Intravitreal injection; Ranibizumab;
مقالات ISI رانیبیزوماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: رانیبیزوماب; Neovascular AMD; Incidence; Ranibizumab; Anatomic classification; Optical coherence tomography; DMAE neovascular; Incidencia; Ranibizumab; Clasificación anatómica; TomografÃa de coherencia óptica;
Keywords: رانیبیزوماب; APTC; Antiplatelet Trialists' Collaboration; ATE; arterial thromboembolic event; CBV; cerebrovascular; CI; confidence interval; CV; cardiovascular; EPAR; European Public Assessment Report; ICD-9-CM; International Classification of Diseases, Ninth Revision
Keywords: رانیبیزوماب; AE; adverse event; BCVA; best-corrected visual acuity; DME; diabetic macular edema; DR; diabetic retinopathy; DRSS; Diabetic Retinopathy Severity Scale; ETDRS; Early Treatment Diabetic Retinopathy Study; HbA1c; hemoglobin A1c; NPDR; nonproliferative diabe
Keywords: رانیبیزوماب; Photodynamic therapy; Ranibizumab; Age-related macular degeneration; Systematic review; Meta-analysis;
Keywords: رانیبیزوماب; Anti-VEGF; Diabetic macular edema; Diabetic retinopathy; Dry retina; Ranibizumab; Anti-VEGF; Ådème maculaire diabétique; Rétinopathie diabétique; Assèchement rétinien; Ranibizumab;
Keywords: رانیبیزوماب; Degeneración macular asociada; Protocolo Pro Re Nata; Pauta «tratar y extender»; Ranibizumab; Agudeza visual; Retratamiento; Neovascular AMD; PRN regimen; Treat-and-extend regimen; Ranibizumab; Visual acuity; Re-treatment;
Keywords: رانیبیزوماب; AV; arteriovenous; BCVA; best-corrected visual acuity; BRAVO; RanibizumaB for the treatment of macular edema following bRAnch retinal Vein Occlusion; BRVO; branch retinal vein occlusion; BVOS; Branch Vein Occlusion Study; CFT; central foveal thickness; CP
Keywords: رانیبیزوماب; Lipid implants; Twin-screw extrusion; Sustained release; Protein stability; Ranibizumab; Monoclonal antibody;
Keywords: رانیبیزوماب; Photodynamic therapy; Ranibizumab; Polypoidal choroidal vasculopathy; Meta-analysis; Systematic review;
Keywords: رانیبیزوماب; Macular edema; Retinal vein occlusion; Retinal venous oxygen saturation; Retinal oximetry; Optical coherence tomography; Ranibizumab; Ådème maculaire; Occlusion veineuse rétinienne; Saturation veineuse rétinienne en oxygène; Oxymétrie de la rétine;
Keywords: رانیبیزوماب; subretinal hemorrhage; neovascular age-related macular degeneration; anti-vascular endothelial growth factor; bevacizumab; ranibizumab; tissue plasminogen activator; pneumatic displacement; vitrectomy; gas; macular translocation
Keywords: رانیبیزوماب; aflibercept; bevacizumab; diabetes; diabetic macular edema; diabetic retinopathy; intravitreal anti-VEGF; laser photocoagulation; ranibizumab; retina; vascular endothelial growth factor; VEGF;
Keywords: رانیبیزوماب; aflibercept; Avastin™; bevacizumab; diabetic macular edema; diabetic retinopathy; glycated hemoglobin (A1C); insulin therapy; metabolic parameters; ranibizumab; VEGF-inhibitorsaflibercept; AvastinMC; bévacizumab; œdème maculaire diabétique; hémoglobine gl
Keywords: رانیبیزوماب; Diabetes; RETÄ°NOPATHY; Quality of life; Laser; Ranibizumab;
Keywords: رانیبیزوماب; Intravitreal dexamethasone implant; Ranibizumab; Macular edema; Diabetes mellitus; Optical coherence tomography; Visual acuityImplante de dexametasona intravítreo; Edema macular; Diabetes mellitus; Tomografía de coherencia óptica; Agudeza visual
Keywords: رانیبیزوماب; Nanotechnology; Nanoparticles; Retina; Vitreous; Sustained release; AMDCyclosporine A; Difluprednate; Aflibercept; Bevacizumab; Pegaptanib; Ranibizumab
Keywords: رانیبیزوماب; AMD; age-related macular degeneration; BCVA; best-corrected visual acuity; BRVO; branch retinal vein occlusion; CRVO; central retinal vein occlusion; CST; central subfield thickness; OCT; optical coherence tomography; PRN; pro re nata; RBZ; ranibizumab; R
Keywords: رانیبیزوماب; angiogenesis; glaucoma; glaucoma filtration surgery; neovascular glaucoma; anti-VEGF therapy; bevacizumab; ranibizumab; anti-metabolites
Keywords: رانیبیزوماب; anti-VEGF; bevacizumab; Histoplasma capsulatum; histoplasmosis; ocular histoplasmosis syndrome; photocoagulation; photodynamic therapy; presumed ocular histoplasmosis syndrome; ranibizumab; submacular surgery;
Keywords: رانیبیزوماب; age-related macular degeneration; antivascular endothelial growth factor; bevacizumab; glaucoma; intravitreal injections; ocular hypertension; ranibizumab
Keywords: رانیبیزوماب; Homeopatía; Degeneración macular asociada a la edad; Ceguera; RanibizumabHomeopathy; Age related macular degeneration; Blindness; Ranibizumab
Keywords: رانیبیزوماب; aflibercept; age-related macular degeneration; pegaptanib; ranibizumab; vascular endothelial growth factor
Keywords: رانیبیزوماب; Neovascularización; Bevacizumab; Ranibizumab; Córnea; Antifactor de crecimiento vascular endotelialNeovascularization; Bevacizumab; Ranibizumab; Cornea; Anti-vascular endothelial growth factor
Keywords: رانیبیزوماب; Poly(lactide-co-glycolide); Poly(ethylene glycol); Fluorescein isothiocyanate-dextran; Polyethyleneimine; Bevacizumab; Ranibizumab; Verteporfin (PubChem CID: 5362420); Rostaporfin (PubChem CID: 23725012); Methoxypoly(ethylene glycol)-poly(β-caprolactone);
Keywords: رانیبیزوماب; corneal transplantation; graft rejection; ranibizumab; skin graft; vascular endothelial growth factor antibody; BN; Brown Norway; FGF; fibroblast growth factor; IL; interleukin; MMPs; matrix metalloproteinases; PDGF; platelet-derived growth factor; SD; Sp
Keywords: رانیبیزوماب; Choroidal neovascularization; Morning glory syndrome; Ranibizumab
Keywords: رانیبیزوماب; Choroidal osteoma; Anti-VEGF; Ranibizumab; Choroidal neovascularization
Keywords: رانیبیزوماب; Biological marker; Mass spectrometry; Protein; Proteomics; Ranibizumab; Retina; Retinal vein occlusion; Vascular endothelial growth factor; Integrin
Keywords: رانیبیزوماب; Age-related macular degeneration; Cataract; Lens; Pseudophakia; Ranibizumab; Visual acuity
Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: An angiographic illustration
Keywords: رانیبیزوماب; Anti-VEGF; Proliferative diabetic retinopathy; Retinal reperfusion; Ranibizumab; Protocol-S;
Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE
Keywords: رانیبیزوماب; BCVA; best-corrected visual acuity; CST; central subfield thickness; DA; disc area; DME; diabetic macular edema; DR; diabetic retinopathy; ETDRS; Early Treatment for Diabetic Retinopathy Study; FA; fluorescein angiogram; FAZ; foveal avascular zone; MNP; m
Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)
Keywords: رانیبیزوماب; AE; adverse event; BCVA; best-corrected visual acuity; DA; disc area; DME; diabetic macular edema; ETDRS; Early Treatment Diabetic Retinopathy Study; FAS; full analysis set; HbA1C; glycated hemoglobin; HR-PDR; high-risk proliferative diabetic retinopathy;
Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration
Keywords: رانیبیزوماب; age-related macular degeneration; vascular endothelial growth factor; ranibizumab; lucentis; aflibercept; eylea; switch; refractory;
Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy
Keywords: رانیبیزوماب; Magnetic nanoparticles; PEG-PLGA; Age-related macular degeneration; Ranibizumab; Drug delivery;
Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria
Keywords: رانیبیزوماب; Phagocytosis; Latex beads; Bevacizumab; Ranibizumab; Aflibercept; Anti-VEGF; Cybrids; Retinal pigment epithelium; Mitochondria; Age-related macular degeneration;
Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium
Keywords: رانیبیزوماب; Bevacizumab; Ranibizumab; Aflibercept; Rituximab; RPE; Senescence; Aging;
Comparative study of anti-VEGF Ranibizumab and Interleukin-6 receptor antagonist Tocilizumab in Adjuvant-induced Arthritis
Keywords: رانیبیزوماب; Adjuvant induced arthritis; Ranibizumab; Tocilizumab; Immune Response;
Enfermedad de Coats con edema macular sensible al aflibercept y láser argón
Keywords: رانیبیزوماب; Enfermedad de Coats; Láser argón; Ranibizumab; Aflibercept; Coats' disease; Argon laser; Ranibizumab; Aflibercept;
Ranibizumab biosimilar/polyethyleneglycol-conjugated gold nanoparticles as a novel drug delivery platform for age-related macular degeneration
Keywords: رانیبیزوماب; Age-related macular degeneration; Biosimilar; Gold nanoparticles; PEGylation; Ranibizumab;
Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
Keywords: رانیبیزوماب; Anti-VEGF; Bevacizumab; Ranibizumab; Aflibercept; Cornea;
Réponse visuelle et anatomique en condition de « vraie vie » du traitement par aflibercept chez les patients naïfs atteints de dégénérescence maculaire liée à l'âge exsudative
Keywords: رانیبیزوماب; Dégénérescence maculaire liée à l'âge exsudative; Patient naïf; Aflibercept; Ranibizumab; Anti-VEGF; Acuité visuelle; Ãpaisseur maculaire centrale; Exudative age-related macular degeneration; Treatment-naive patient; Aflibercept; Ranibizumab; A
Traitement par ranibizumab des néovascularisations choroïdiennes secondaires à un pseudoxanthome élastique : résultats de l'étude observationnelle française PiXEL
Keywords: رانیبیزوماب; Néovascularisation choroïdienne; Pseudoxanthome élastique; Ranibizumab; Meilleure acuité visuelle corrigée; Stabilisation; Choroidal neovascularization; Pseudoxanthoma elasticum; Ranibizumab; Best-corrected visual acuity; Stabilization;
Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
Keywords: رانیبیزوماب; Ranibizumab; Aflibercept; Age-related macular degeneration;
Müller glia activation by VEGF-antagonizing drugs: An in vitro study on rat primary retinal cultures
Keywords: رانیبیزوماب; Müller glia; Primary retinal cultures; Vascular Endothelial Growth Factor; Glial Fibrillary Acidic Protein; Aquaporin 4; K+ channel 4.1; Aflibercept; Ranibizumab; VEGF; Vascular Endothelial Growth Factor; GFAP; Glial Fibrillary Acidic Protein; ERK 1/2; E
Quantification of the vascular endothelial growth factor with a bioluminescence resonance energy transfer (BRET) based single molecule biosensor
Keywords: رانیبیزوماب; Vascular endothelial growth factor (VEGF); Bioluminescence resonance energy transfer (BRET); Single chain variable fragment (scFv); Ranibizumab;
Ranibizumab interacts with the VEGF-A/VEGFR-2 signaling pathway in human RPE cells at different levels
Keywords: رانیبیزوماب; VEGF-A; vascular endothelial growth factor A; VEGFR-2; vascular endothelial growth factor receptor 2; RPE; retinal pigment epithelium; AMD; age-related macular degeneration; Ranibizumab; RPE; VEGF-A; VEGFR-2; Oxidative stress;
Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study
Keywords: رانیبیزوماب; BCVA; best-corrected visual acuity; CFT; central foveal thickness; DME; diabetic macular edema; ETDRS; Early Treatment Diabetic Retinopathy Study; FDA; Food and Drug Administration; OCT; optical coherence tomography; PRN; pro re nata; RBZ; ranibizumab; RE
Ranibizumab et dégénérescence maculaire liée à l'âge exsudative : analyse multicentrique à 5 ans des résultats fonctionnels et anatomiques en pratique clinique réelle
Keywords: رانیبیزوماب; Anti-VEGF; Dégénérescence maculaire liée à l'âge exsudative; Suivi à long terme; Régime PRN; Ranibizumab; Anti-vascular endothelial growth factor; Exudative age-related macular degeneration; Long-term follow-up; PRN regimen; Ranibizumab;
Response to anti-VEGF-A treatment of endothelial cells in vitro
Keywords: رانیبیزوماب; VEGF; Endothelial cells; Ranibizumab; Aflibercept; Neovascularization;